We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-2.06%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$268M
AUM Growth
-$59.5M
(-18%)
Cap. Flow
-$50.9M
Cap. Flow
% of AUM
-19%
Top 10 Holdings %
Top 10 Hldgs %
44.52%
Holding
92
New
17
Increased
19
Reduced
32
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$9.9M |
| 2 |
Abbott
ABT
|
+$8.03M |
| 3 |
Johnson & Johnson
JNJ
|
+$7.21M |
| 4 |
Becton Dickinson
BDX
|
+$6.5M |
| 5 |
Elevance Health
ELV
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$9.44M |
| 2 |
Danaher
DHR
|
+$9.11M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$7.69M |
| 4 |
VanEck Biotech ETF
BBH
|
+$6.22M |
| 5 |
Sabra Healthcare REIT
SBRA
|
+$6.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.35% |
| 2 | Real Estate | 1.88% |
| 3 | Financials | 1.53% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ocular Therapeutix
OCUL
$1.88B
| $1.16M | 0.43% |
+178,461
| New | +$1M |
|
52
Icon
ICLR
$12.1B
| $992K | 0.37% |
+8,400
| New | +$963K |
|
|
BLCM
53
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $947K | 0.35% |
+14,430
| New | +$1.09M |
|
|
NVRO
54
DELISTED
NEVRO CORP.
NVRO
| $927K | 0.35% |
10,701
-16,260
| -60% | -$1.31M |
|
55
Teleflex
TFX
$6.19B
| $918K | 0.34% |
+3,600
| New | +$946K |
|
56
Jazz Pharmaceuticals
JAZZ
$15.6B
| $770K | 0.29% |
5,100
+150
| +3% | +$22K |
|
57
Regeneron Pharmaceuticals
REGN
$78B
| $758K | 0.28% |
2,200
-3,400
| -61% | -$1.18M |
|
|
RDUS
58
DELISTED
Radius Health, Inc.
RDUS
| $686K | 0.26% |
19,100
-22,300
| -54% | -$806K |
|
59
Dentsply Sirona
XRAY
$2.83B
| $664K | 0.25% |
+13,200
| New | +$777K |
|
60
Qiagen
QGEN
$8.56B
| $662K | 0.25% |
+19,333
| New | +$679K |
|
|
ZGNX
61
DELISTED
Zogenix, Inc.
ZGNX
| $653K | 0.24% |
16,300
-3,700
| -19% | -$147K |
|
|
RNTX
62
Rein Therapeutics
RNTX
$67.2M
| $615K | 0.23% |
3,785
-515
| -12% | -$91.8K |
|
|
MDCO
63
DELISTED
Medicines Co
MDCO
| $560K | 0.21% |
17,000
-24,200
| -59% | -$756K |
|
64
Viking Therapeutics
VKTX
$3.89B
| $520K | 0.19% |
+119,100
| New | +$659K |
|
|
RETA
65
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $513K | 0.19% |
+25,000
| New | +$643K |
|
|
AVDL
66
DELISTED
Avadel Pharmaceuticals
AVDL
| $406K | 0.15% |
+55,700
| New | +$490K |
|
|
AKTX
67
Akari Therapeutics
AKTX
$13.1M
| $359K | 0.13% |
247
-4
| -2% | -$8.64K |
|
68
AnaptysBio
ANAB
$1.62B
| $326K | 0.12% |
3,130
-6,570
| -68% | -$740K |
|
|
APLS
69
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-17,600
| Closed | -$382K |
|
70
Assembly Biosciences
ASMB
$513M
| – | – |
-792
| Closed | -$430K |
|
71
Ascendis Pharma A/S
ASND
$15.8B
| – | – |
-37,828
| Closed | -$1.51M |
|
|
72
VanEck Biotech ETF
BBH
$400M
| – | – |
-49,899
| Closed | -$6.22M |
|
73
Biogen
BIIB
$30.3B
| – | – |
-15,399
| Closed | -$4.91M |
|
74
BioMarin Pharmaceuticals
BMRN
$11.7B
| – | – |
-10,100
| Closed | -$901K |
|
75
Cencora
COR
$59.5B
| – | – |
-55,240
| Closed | -$5.07M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Endurant Capital Management held 92 positions worth $268M, down 18% from $327M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Endurant Capital Management withdrew a net $50.9M in Q1 2018, closing 23 positions and reducing 32 holdings. Its most notable exit was VanEck Biotech ETF, an estimated $6.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 86% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Endurant Capital Management opened a new position in Universal Health Services worth $9.88M.
- Endurant Capital Management's largest Q1 2018 buy was Universal Health Services: 83,400 shares worth $9.88M.
- Endurant Capital Management added most to Abbott in Q1 2018, an estimated $8.03M increase.
- Endurant Capital Management's biggest Q1 2018 reduction was McKesson, cutting an estimated $9.44M.
- Endurant Capital Management fully exited VanEck Biotech ETF in Q1 2018, selling an estimated $6.22M.
- Endurant Capital Management's ten largest holdings make up 45% of its $268M portfolio in Q1 2018.
- Endurant Capital Management opened 17 new positions and closed 23 in Q1 2018.
- Endurant Capital Management's portfolio value fell 18% quarter-over-quarter to $268M.
Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.